These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
266 related articles for article (PubMed ID: 10087434)
21. Recombinant activated factor VII (rFVIIa) therapy for intracranial hemorrhage in hemophilia A patients with inhibitors. Schmidt ML; Gamerman S; Smith HE; Scott JP; DiMichele DM Am J Hematol; 1994 Sep; 47(1):36-40. PubMed ID: 8042614 [TBL] [Abstract][Full Text] [Related]
23. Assessment of individual dose utilization vs. physician prescribing recommendations for recombinant activated factor VII (rFVIIa) in paediatric and adult patients with congenital haemophilia and alloantibody inhibitors (CHwI): the Dosing Observational Study in Hemophilia (DOSE). Gruppo RA; Kessler CM; Neufeld EJ; Cooper DL Haemophilia; 2013 Jul; 19(4):524-32. PubMed ID: 23551918 [TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and safety of a 270 mcg kg-1 dose of room temperature stable recombinant activated factor VII in patients with haemophilia. Morfini M; Bjerre J Haemophilia; 2011 Nov; 17(6):860-6. PubMed ID: 21371194 [TBL] [Abstract][Full Text] [Related]
25. Exposure and safety of higher doses of recombinant factor VIIa ≥250 μg kg(-1) in individuals with congenital haemophilia complicated by alloantibody inhibitors: the Haemophilia and Thrombosis Research Society Registry experience (2004-2008). Neufeld EJ; Kessler CM; Gill JC; Wilke CT; Cooper DL; Haemophilia; 2011 Jul; 17(4):650-6. PubMed ID: 21299750 [TBL] [Abstract][Full Text] [Related]
26. A Comparison of Efficacy Between Recombinant Activated Factor VII (Aryoseven) and Novoseven in Patients With Hereditary FVIII Deficiency With Inhibitor. Faranoush M; Abolghasemi H; Mahboudi F; Toogeh G; Karimi M; Eshghi P; Managhchi M; Hoorfar H; Dehdezi BK; Mehrvar A; Khoeiny B; Vaziri B; Kamyar K; Heshmat R; Baghaeipour MR; Mirbehbahani NB; Fayazfar R; Ahmadinejad M; Naderi M Clin Appl Thromb Hemost; 2016 Mar; 22(2):184-90. PubMed ID: 25343955 [TBL] [Abstract][Full Text] [Related]
27. Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors. Shirahata A; Kamiya T; Takamatsu J; Kojima T; Fukutake K; Arai M; Hanabusa H; Tagami H; Yoshioka A; Shima GM; Naka GH; Fujita GS; Minamoto Y; Kamizono J; Saito H Int J Hematol; 2001 Jun; 73(4):517-25. PubMed ID: 11503968 [TBL] [Abstract][Full Text] [Related]
28. Prospective, randomised trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Shapiro AD; Gilchrist GS; Hoots WK; Cooper HA; Gastineau DA Thromb Haemost; 1998 Nov; 80(5):773-8. PubMed ID: 9843170 [TBL] [Abstract][Full Text] [Related]
29. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. Gruppo RA; Malan D; Kapocsi J; Nemes L; Hay CRM; Boggio L; Chowdary P; Tagariello G; von Drygalski A; Hua F; Scaramozza M; Arkin S; J Thromb Haemost; 2018 Oct; 16(10):1984-1993. PubMed ID: 30151972 [TBL] [Abstract][Full Text] [Related]
30. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage. Brady KM; Easley RB; Tobias JD Paediatr Anaesth; 2006 Oct; 16(10):1042-6. PubMed ID: 16972833 [TBL] [Abstract][Full Text] [Related]
31. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors. Smith OP Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():22-5. PubMed ID: 12214142 [TBL] [Abstract][Full Text] [Related]
32. Single-center experience: use of recombinant factor VIIa for acute life-threatening bleeding in children without congenital hemorrhagic disorder. Yilmaz D; Karapinar B; Balkan C; Akisü M; Kavakli K Pediatr Hematol Oncol; 2008 Jun; 25(4):301-11. PubMed ID: 18484474 [TBL] [Abstract][Full Text] [Related]
33. Results of the WIRK prospective, non-interventional observational study of recombinant activated factor VII (rFVIIa) in patients with congenital haemophilia with inhibitors and other bleeding disorders. Birschmann I; Klamroth R; Eichler H; Schenk J; Kirchmaier CM; Halimeh S Haemophilia; 2013 Sep; 19(5):679-85. PubMed ID: 23647644 [TBL] [Abstract][Full Text] [Related]
34. Single higher dose of recombinant activated factor VII in the treatment of hemorrhages in patients with hemophilia complicated by inhibitors. Łaguna P; Mital A Adv Clin Exp Med; 2012; 21(4):519-24. PubMed ID: 23240458 [TBL] [Abstract][Full Text] [Related]
35. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25 degrees C stable formulation. Bysted BV; Scharling B; Møller T; Hansen BL Haemophilia; 2007 Sep; 13(5):527-32. PubMed ID: 17880439 [TBL] [Abstract][Full Text] [Related]